RWMA Stock Overview
Develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Rockwell Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$4.56 |
| 52 Week Low | US$0.85 |
| Beta | 1.64 |
| 1 Month Change | -4.83% |
| 3 Month Change | -51.00% |
| 1 Year Change | -45.72% |
| 3 Year Change | -48.09% |
| 5 Year Change | -95.84% |
| Change since IPO | -99.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| RWMA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -16.0% | 4.7% | 0.8% |
| 1Y | -45.7% | -8.9% | 14.6% |
Return vs Industry: RWMA underperformed the German Medical Equipment industry which returned -8.9% over the past year.
Return vs Market: RWMA underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| RWMA volatility | |
|---|---|
| RWMA Average Weekly Movement | 13.2% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: RWMA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RWMA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 244 | Mark Strobeck | www.rockwellmed.com |
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.
Rockwell Medical, Inc. Fundamentals Summary
| RWMA fundamental statistics | |
|---|---|
| Market cap | €30.85m |
| Earnings (TTM) | -€507.65k |
| Revenue (TTM) | €87.65m |
0.4x
P/S Ratio-60.8x
P/E RatioIs RWMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RWMA income statement (TTM) | |
|---|---|
| Revenue | US$97.73m |
| Cost of Revenue | US$80.27m |
| Gross Profit | US$17.46m |
| Other Expenses | US$18.03m |
| Earnings | -US$566.00k |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 17.87% |
| Net Profit Margin | -0.58% |
| Debt/Equity Ratio | 26.8% |
How did RWMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 04:07 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rockwell Medical, Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Ritu Baral | Canaccord Genuity |